1198 results about "Dermatologic disorders" patented technology

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

The invention relates to a cosmetic or dermatological composition containing a carrier comprising at least one fatty phase characterized in that it contains at least one derivative or a mixture of derivatives of 1,7-diphenyl-3,5-heptanedione having a particular structure and at least one oil having, in its structure, at least one amide unit.The invention also relates to its uses in cosmetics and dermatology, in particular for preventing or combating the harmful effects of UV radiation and pollution on human keratinous materials, and more particularly for preventing and / or treating photoaging of the skin.The invention also relates to a method for solubilizing a derivative or a mixture of derivatives of 1,7-diphenyl-3,5-heptanedione having a particular structure with at least one oil having, in its structure, at least one amide unit.

A topical spray or foam, methods of making the formulation, and methods of use thereof, has been developed. In one preferred embodiment, the composition includes one or more active agents and exhibits both antibacterial activity and antifungal activity. Excipients such as chemical disinfectants, anti-pruritic agents to minimize itching, and skin protective compounds may be added. The composition may be formulated to be dispensed as a spray or foam and the spray or foam may be administered either by a hand pump or by an aerosolizing propellant. A second single phase formulation has also been developed. The formulation comprises a first drug which is water soluble or hydrophilic and a second drug which is lipid soluble or hydrophobic, wherein at least one of the drugs is bound to an ion-exchange resin. The use of binding resins, such as ion-exchange resins, allows drugs with incompatible solvent requirements to be prepared in a single-phase formulation.

The present invention is a cosmetic or dermatological preparation for use with a dispenser that includes an auxiliary to keep the dispenser operating smoothly. The auxiliary is selected from the group consisting of (i) polyols having 2 to 6 carbon atoms and 2 to 6 hydroxyl or alkoxy groups and (ii) surfactants that reduce the surface tension of the preparation to less than 30 mN / m. The preparation is particularly suitable with a dispenser comprising a container and an inner container wall for housing a cosmetic or dermatological preparation; a follow-up plunger on a base side of the dispenser, which is capable of being slidably displaced on the inner container wall under the pressure of the ambient atmosphere; a head section on a top end of the dispenser that can be slidably displaced in relation to the container and that comprises a dispensing channel, the dispensing channel capable of being connected in a communicating manner to the container; a manually actuable delivery device comprising a variable-volume delivery chamber, a delivery element that can be displaced longitudinally in relation to the container and the head section, comprising a delivery plunger that can be slidably displaced within the delivery chamber and a delivery stem connected to the delivery plunger, and a delivery channel circumferentially enclosed by the delivery stem and comprising a delivery-channel inlet opening communicating with the delivery chamber and a delivery-channel outlet opening. The delivery channel outlet opening is capable of being moved into an open position relative to the dispensing channel by displacing the delivery element.

Compositions comprising oligosaccharide aldonic acids are useful for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and / or extrinsic aging, as well as with changes or damage caused by extrinsic factors; general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa; for general oral care, as well as treatment and prevention of oral and gum diseases; and for wound healing of the skin. Compositions comprising oligosaccharide aldonic acids may further comprise a cosmetic, pharmaceutical or other topical agent to enhance or create synergetic effects.

The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

A device, applicator and a cosmetic non-therapeutic method of treating at least one area of the human body. The device includes a composition held in a container or a substrate and an applicator configured to apply the composition. The applicator includes an application surface that includes an application surface material with at least one of a thermal inertia of at least 1,000 Jm−2K−1s−1 / 2 and a thermal conductivity greater than or equal to 1 Wm−1K−1. The method includes providing an applicator, cooling the applicator to a temperature below or equal to 15° C., and loading the cooled applicator with a cosmetic composition at a temperature closer to an ambient temperature than that of the applicator, and applying the composition using the applicator, or before or after the cooling, applying a cosmetic composition, and after the cooling, bringing the cooled applicator into contact with the area to be treated.

The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The disclosure provides compositions and methods for the treatment of skin disorders using microbial compositions to a subject.

A dermatological treatment apparatus is disclosed that is cordless and sufficiently compact as to be hand-held. A self-contained housing is configured for gripping by a person's hand for cordless manipulation in a dermatologic treatment procedure. A light source and electrical circuit are contained within the housing. The circuit includes one or more batteries and an electronic control circuit for energizing the light source to produce output light pulses. A light path is within the housing including an aperture through which the output light pulses are propagated out of the housing having properties sufficient for providing efficacious treatment.

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjogren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

The present invention provides a skin surface imaging system for capturing at least one image of the skin of a patient's body, comprising: a. a base; b. a plurality of image sensors, connectable to said base, arranged in a predetermined arrangement; each of said image sensors adapted to capture an image of a predetermined area of said body, so that as a set of images is provided; and, c. a processing unit communicatable with said image sensors, comprising a program of machine-readable instructions embodied on a computer readable memory and executable by a digital data processor adapted to: (i) collect said set of images from said image sensors; (ii) analyze said set of images; (iii) construct a record of personal data associated with the skin of said body of said patient; and (iv) output a dermatological data associated with said skin of said body.

The invention relates to the use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions, specifically to the use of at least one compound derived from para-coumaric acid having a general formula (I) below: in which, especially, Z represents an oxygen or an —NH— group; X and Y are identical and each represent a CH or CH2 group, as an active principle with depigmenting, free-radical-scavenging and / or antiinflammatory activity. The invention also relates to the use of the above compounds for cosmetic care or for the preparation of a pharmaceutical composition, especially for depigmenting an area of skin, having antiradical and / or antiinflammatory activity.

Topically applicable dermatological / cosmetic compositions suited for ungual / peri-ungual administration for the treatment of a variety of pathologies, including fungal pathologies, such as onychomycosis, contain (a) at least one biologically active agent (e.g., antifungal) and (b) at least two of the pro-penetrating agents selected from the group consisting of urea, an organic acid and an ethoxydiglycol, the at least two-pro-penetrating agents respectively being present in effective amounts as to synergistically improve the ungual / peri-ungual bioavailability of the at least one biologically active agent.

Stable personal care composition comprising hydrophobic modified silica, a particulate material and a dermatologically-acceptable carrier, said carrier comprising about 70% or greater, by weight of the carrier, of at least one water-soluble polyol, said water-soluble polyol having a solubility parameter of from about 11 to about 17.

The present invention relates to pharmaceutical, therapeutic, nutritional, cosmetic, and dermatological compositions derived from the preicarp (rind) of the Garcinia mangostana L plant and the novel extraction processes used to produce those compositions. Specifically, the present invention relates, in part, to an approximately 0.01% to about 80% mixture of a xanthone-rich mangosteen pericarp (rind) extract in novel combinations for pharmaceutical, cosmetic, therapeutic or dermatological compositions that yield surprising health benefits. Additionally, the present invention relates, in part, to novel extraction processes that result in the production of the novel compositions of the invention.

The invention discloses multi-herb antibacterial liquid, relates to an external medicament for treating skin diseases and a preparation method thereof, and belongs to a medical external medicament. The external liquid medicine for treating various skin diseases comprises the following medicinal components by weight: 10-20 g of folium artemisiae argyi, 10-15 g of white mulberry branch, 10-15 g of angelica root, 10-15 g of galanga, 5-20 g of isatis root, 10-15 g of mint, 10-15 g of schizonepeta, 10-15 g of lithospermum, 5-15 g of fructus forsythiaev, 10-20 g of cortex dictamni, 10-15 g of rhizoma atractylodis, 10-15 g of tuber of stemona, 10-15 g of corktree, 10-20 g of cicada slough, 10-20 g of honeysuckle, 10-15 g of divaricate saposhnikovia root, 10-15 g of scutellaria baicalensis, 10-20 g of sophora flower, 5-15 g of pepper, 10-15 g of root-bark of Chinese wolfberry, 10-15 g of seed of Job's tears, 10-15 g of cinnamon, 10-15 g of coptis, 10-20 g of astragalus root, 10-15 g of golden larch bark, 10-15 g of rhubarb, 10-20 g of safflower, 10-20 g of radix sophorae flavescentis, 10-15 g of ephedra, 5-15 g of black snake, 10-20 g of angelica, 10-15 g of asarum, 10-15 g of vermilion, 5-10 g of borneol, 5-15 g of long-noded pit viper, 10-15 g of saponin, 5-10 g of cantharis, 10-15 g of fructus cnidii and 3,200 ml of 60-degree spirit brewed from store-up grains. A product provided by the invention is dark brown liquid and has the smell of Chinese herbal medicines and mild fragrance of wine. The 39 raw material medicaments included in the product are processed through seven operation processes.

Modified VEGF proteins that inhibit VEGF-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit VEGF-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders.

PEG-free, cold-preparable, prolonged-stability, low-viscosity, fine oil-in-water emulsions, their preparation from preferably clear oil phases or via preferably clear to transparent microemulsion-like concentrates, the corresponding oil phases or microemulsion-like concentrates and the use of the inventive emulsions for producing cosmetic, dermatological, pharmaceutical or industrial formulations, especially for the production of impregnating emulsions for wet wipes or for sprayable care emulsions are provided.

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor PTHR1, also known as parathyroid hormone / parathyroid hormone related protein receptor. The PTHR1 compounds are derived from the intracellular loops and domains of the PTHR1 receptor. The invention also relates to the use of these PTHR1 receptor compounds and pharmaceutical compositions comprising the PTHR1 receptor compounds in the treatment of diseases and conditions associated with PTHR1 receptor modulation, such as osteoporosis; humoral hypercalcemia of malignancy; osteolytic and osteoblastic metastasis to bone; primary and secondary hyperparathyroidism associated increase in bone absorption; vascular calcification; psychiatric disorders and cognitive disorders associated with hyperparathyroidism; dermatological disorders; and excess hair growth.

An emulsion for topical application to the skin containing a high molecular weight emulsifier and substantially no emulsifiers of a molecular weight less than 100 kD. The emulsion may be used to prevent or treat dermatoses and may additionally contain pharmaceutically active ingredients.

The methods and applications of a surface plasmon resonance-enhanced marking technique are disclosed. The technique uses surface plasmon resonance (SPR) excited nanoparticles and a surface plasmon resonance source in nonlinear interactions with nearby chemical substances and medium for marking purposes. The SPR-enhanced absorption and fluorescence rates of chemical substances or medium and nonlinearity of SPR interactions with chemical substances or medium make the proposed method suitable for marking fragile materials including biomaterials, such as writing on thin plastic foils or DNA-protein crosslinking. The marking method can also be applied to a three-dimensional recording and read out information system with subwavelength resolutions, coding information of secrete documents, drug delivery, tissue surgery, tattoo writing or removal, photodynamic therapy, cosmetic and dermatological treatment.

The present invention is a cosmetic or dermatological preparation for use with a dispenser system that includes at least 0.01% by weight of one or more hydrocolloids. The preparation is particularly suitable with a dispenser comprising an essentially cylindrical container and an inner container wall for housing a cosmetic or dermatological preparation; a follow-up plunger on a base side of the dispenser, which is capable of being slidably displaced on the inner container wall under the pressure of the ambient atmosphere; a head section on a top end of the dispenser that can be slidably displaced in relation to the container and that comprises a dispensing channel, the dispensing channel capable of being connected in a communicating manner to the container; a manually actuable delivery device comprising a variable-volume delivery chamber, a delivery element that can be displaced longitudinally in relation to the container and the head section, comprising a delivery plunger that can be slidably displaced within the delivery chamber and a delivery stem connected to the delivery plunger, and a delivery channel circumferentially enclosed by the delivery stem and comprising a delivery-channel inlet opening communicating with the delivery chamber and a delivery-channel outlet opening. The delivery channel outlet opening is capable of being moved into an open position relative to the dispensing channel by displacing the delivery element.

The present invention discloses compounds according to Formula I:Wherein R1a, R1b, R2, R4, R5, R6a, R6b, R7, R8, W, X, Cy, and the subscript a are as defined herein.The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

Formulations containing plant extracts, in particular Astragalus extracts, and their use in inducing telomerase activity in cells, are described. Such compositions include pharmaceutical, including topical, and nutraceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in selected cells, such as, for example, HIV infection, various degenerative diseases, and acute or chronic skin ailments. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and proliferation of stem cells. Also described are cosmetic formulations of such extracts for conditioning the skin.